Authors
Michinori Ogura, Kiyoshi Ando, Nozomi Niitsu, Seok Jin Kim, Ken Ohmachi, Naoki Takahashi, Toshiki Uchida, Naoto Takahashi, Naokuni Uike, Hyeon Seok Eom, Yee Soo Chae, Takashi Terauchi, Ukihide Tateishi, Mitsuaki Tatsumi, Won Seog Kim, Cheolwon Suh, Kensei Tobinai, Japanese and Korean Bendamustine Lymphoma Study Group
Publication date
2012/5/20
Source
Journal of Clinical Oncology
Volume
30
Issue
15_suppl
Pages
8023-8023
Publisher
American Society of Clinical Oncology
Description
8023
Background: Effective salvage therapies are needed in patients (pts) with relapsed/refractory DLBCL after R-CHOP. Therapy with bendamustine plus rituximab (B-R) was well tolerated and effective in the preceding phase I study in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, including DLBCL. This phase II study assessed the efficacy and safety of B-R in pts with relapsed/refractory DLBCL. Methods: Pts with histologically confirmed DLBCL (excluding transformed disease) and 1-3 prior therapies received rituximab 375 mg/m2 IV on day 1 and bendamustine 120 mg/m2 IV on days 2 and 3 of each 21-day cycle, for up to 6 cycles. Recovery of neutrophil count to ≥1,000/mm3 and platelet count to ≥75,000/mm3 were required prior to the start of each cycle; treatment delays >2 weeks resulted in discontinuation. The primary endpoint was overall response rate (ORR); secondary endpoints …
Total citations
Scholar articles
M Ogura, K Ando, N Niitsu, SJ Kim, K Ohmachi… - 2012